Search
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.
Call for interest — new La Cantera event
The call for interest is open until 23:59 on November 30, 2024. Complete the Word application form now
In 2025, EHA will provide funding for a new La Cantera coaching event.
La Cantera coaching
Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.
General Information
June 5, 2025
EHA2025 Congress platform opens
June 12-15, 2025
EHA2025 Milan, Italy - In-person and live stream
Location
Allianz MiCo, Milano Convention Centre
August 15, 2025
EHA2025 Congress platform closes
Scientific Program Committee (SPC) Chair
Prof.
Registration & Accommodation
Registration is now closed. Registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities during breaks and welcome reception
Catering during meeting hours incl.
Clinical Research Training in Hematology
The CRTH 2025 call for applications is now closed. What is Clinical Research Training in Hematology (CRTH)?Clinical Research Training in Hematology (CRTH) provides early-career researchers with a unique, 9-month long training and mentoring experience.
Read more7th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.
Read moreAdolescents and young adults (AYA)
Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.
Read moreSelected EMA news
September 2024Safety update
Withdrawal of Oxbryta (Voxelotor) – marketing authorisation suspended
Treatment of haemolytic anaemia (excessive breakdown of red blood cells) due to sickle cell disease
New medicines approved
Adzynma (rADAMTS13) - orphan medicine
Treatment of congenital thrombotic thrombocytopenic purpura (an inherited clotting disorder)
Other…
Burnout survey
The burnout survey is open until 23:59 on October 11, 2024. Complete the survey now
Burnout in hematologyBurnout is, in broad terms, a state of physical, mental, and emotional exhaustion.